Posted by Michael Wonder on 11 Jun 2025
Azurity Pharmaceuticals announces the FDA approval of Xifyrm (meloxicam injection) for the management of moderate to severe pain in adults
10 June 2025 - Azurity Pharmaceuticals today announced that the US FDA has approved Xifyrm (meloxicam injection), an intravenous non-steroidal anti-inflammatory drug that offers once daily dosing.
Xifyrm is indicated for use in adults for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics.
